About
Oral MDM2 Inhibitor
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (7)
Carl L. Gordon, PhD, CFA
Managing Partner at OrbiMed Advisors
Kartos Therapeutics
team_member
David A. Piacquad
Independent Board Director
Kartos Therapeutics
board_member
Erin Denny, PhD
Head of Oncology Search & Evaluation, Business Development, Amgen
Kartos Therapeutics
team_member
Flavia Borellini, PhD
Independent Board Director
Kartos Therapeutics
board_member
Iain Dukes, MA DPhil
Venture Partner at OrbiMed Advisors
Kartos Therapeutics
team_member
Roger Ulrich, PhD
Senior Advisor at Frazier Healthcare Partners & Scientific Advisor at BioGeneration Ventures
Kartos Therapeutics
advisor
Clinical Trials (17)
View allTotal Trials
17
As Lead Sponsor
16
As Collaborator
1
Total Enrollment
2,050
By Phase
PHASE3: 1PHASE2/PHASE3: 2PHASE1/PHASE2: 8PHASE2: 3PHASE1: 3
By Status
RECRUITING: 5UNKNOWN: 5COMPLETED: 3TERMINATED: 2WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline17 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06479135Lead Sponsor
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
PHASE3Recruiting
600 participants
Started: Jun 3, 2024 · Completed: Dec 31, 2028
NCT05797831Lead Sponsor
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
PHASE2/PHASE3Recruiting
268 participants
Started: Jul 17, 2023 · Completed: Jul 31, 2027
NCT05705466Lead Sponsor
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
PHASE1/PHASE2Withdrawn
Started: Jun 30, 2023 · Completed: Jun 30, 2027
NCT05027867Lead Sponsor
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
PHASE2Terminated
3 participants
Started: Dec 6, 2021 · Completed: Aug 26, 2022
NCT04835584Lead Sponsor
KRT-232 and TKI Study in Chronic Myeloid Leukemia
PHASE1/PHASE2Recruiting
109 participants
Started: May 7, 2021 · Completed: Jun 30, 2026
Locations (1)
Headquarters
Redwood City, CA, United States
Map
Loading map...